Not medical advice. Talk to your provider before using any peptide.
Full disclaimerFour amino acids, an adamantane cap, and a threefold increase in hippocampal neurogenesis in Alzheimer's mice. P21 (also called P021) is a synthetic tetrapeptide carved from residues 148 to 151 of human ciliary neurotrophic factor (CNTF). It crosses the blood-brain barrier after a simple subcutaneous injection. The catch: zero human clinical trials exist. Every dosing number comes from rodent models run in Dr. Khalid Iqbal's lab at the New York State Institute for Basic Research. Community users (roughly 30 to 80 Reddit threads) report subtle memory improvements on the intranasal route, but expectations need calibrating to weeks, not days.
Threefold neurogenesis increase and 50 to 60% tau reduction in triple-transgenic Alzheimer's mice. Those numbers (Kazim and Iqbal 2014)[1] are what put P21 on the nootropic map, despite the compound never entering a single human clinical trial. P21 (P021, no CAS number assigned publicly) is a synthetic tetrapeptide built from residues 148 to 151 of human CNTF. An adamantylated glycine group caps the C-terminus, protecting it from exopeptidase degradation and allowing it to cross the blood-brain barrier. Full-length CNTF is too large to reach the brain and causes weight loss and antibody formation. P21 was engineered specifically to avoid those problems. The mechanism works by removing a brake. Leukemia inhibitory factor (LIF) normally suppresses hippocampal neurogenesis through JAK/STAT3 signaling. P21 competitively blocks that suppression, letting neural progenitor cells proliferate. Downstream, BDNF expression rises, TrkB receptors activate, and CREB phosphorylation increases. Community adoption sits at roughly 30 to 80 Reddit threads across r/nootropics and r/peptides. Most users favor the intranasal route at 500 mcg to 1 mg daily; many report subcutaneous doses below 300 mcg produce no perceivable effect. Reported benefits center on spatial recall and memory consolidation over 3 to 5 weeks. Nobody describes an acute "feel." A 2024 study in a CDKL5 deficiency disorder model [2] found in vitro benefit but failed to replicate neurogenesis or BDNF improvement in vivo. That result raises questions about generalizability across disease contexts. This compound remains strictly experimental with no established human safety profile.
Hippocampal neurogenesis in adults runs under tight regulatory control. One of the brakes is leukemia inhibitory factor (LIF), a pleiotropic cytokine that activates the JAK/STAT3 pathway in neural stem cells and keeps them quiescent in the subgranular zone of the dentate gyrus. P21 competitively inhibits LIF signaling. By blocking that inhibitory input, it releases endogenous neurogenic capacity. Neural progenitor cells that would otherwise sit dormant begin to proliferate and differentiate into mature neurons. The molecular consequences cascade downstream: brain-derived neurotrophic factor (BDNF) expression increases, its high-affinity receptor TrkB activates, and CREB phosphorylation follows. CREB is a master regulator of synaptic plasticity, governing long-term potentiation, dendritic spine formation, and memory consolidation. P21 also reduces glycogen synthase kinase-3 beta (GSK-3B) activity. Lower GSK-3B means less tau hyperphosphorylation, which is a hallmark of Alzheimer's disease pathology. In 3xTg-AD mice, this translated to a 50 to 60% reduction in hyperphosphorylated tau [1]. The adamantylated glycine modification on the C-terminus does double duty. It resists enzymatic breakdown by exopeptidases. It also provides enough lipophilicity to cross the blood-brain barrier after peripheral administration. That structural trick is what separates P21 from full-length CNTF, which cannot reach the brain from systemic circulation. All of this is rodent data. No human pharmacodynamic study has confirmed these pathways activate the same way in the human hippocampus.
Preclinical evidence supports hippocampal neurogenesis (3×), tau hyperphosphorylation reduction (50–60%), and spatial memory improvement in 3xTg-AD and normal adult C57BL/6 mice. A 2024 study [2] in a CDKL5 deficiency disorder model showed in vitro benefit but failed to replicate neurogenesis or BDNF improvement in vivo: suggesting model-specific and potentially disease-context-dependent effects. Zero human clinical trial data exists.
PMID 25485743: Kazim & Iqbal (2014): tau reduction and 3× neurogenesis increase in 3xTg-AD mice over 4–6 weeks of daily dosing
All evidence from rodent models. No Phase I/II/III human trials initiated as of April 2026 (Phanes Biotech in IND-enabling stage only). 2024 negative in vivo result (PMID 39592934) in CDKL5 model raises questions about generalizability across disease contexts. No formal human PK data; half-life is plasma-stability estimate only.
Subtle, cumulative cognitive improvements reported: primarily spatial memory and recall clarity. Intranasal route strongly preferred over SC; many users report no perceivable effect from SC at standard doses. Effects not felt acutely; onset requires 2–4 weeks minimum.
Science demonstrates neurogenesis and tau reduction in AD rodent models; community reports subtle cognitive improvements in healthy adults: mechanistically plausible (PMID 20600002 used normal adult mice) but not directly comparable. SC dosing tiers align between file and community; intranasal dosing diverges substantially (not in calculator). 2024 negative CDKL5 in vivo result adds nuance: effects may be disease/model context-dependent.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 100mcg | Daily |
| Moderate | 300mcg | Daily |
| Aggressive | 500mcg | Daily |
Start subcutaneous if you want to test the waters cheaply. But know that a lot of community users gave up on SC at beginner doses and only found the compound useful intranasally. Reconstitution math for SC: take a 10 mg vial, add 2 mL bacteriostatic water. That gives you 5 mcg per microliter. For the beginner dose (100 mcg), draw 20 units on a U100 insulin syringe. For moderate (300 mcg), draw 60 units. For aggressive (500 mcg), draw 100 units, which is the full syringe. A 5 mg vial with 2 mL BAC water gives 2.5 mcg per microliter; double the units for the same dose. Intranasal is a different calculation entirely. Reconstitute a 5 mg vial with 1 mL BAC water for 5 mg/mL concentration. Each 0.1 mL spray delivers 500 mcg. At the community top protocol of 1 mg/day, a 5 mg vial lasts five days. A 10 mg vial lasts ten days. That's why intranasal cycles get expensive fast, running $18 to $30 per day at 1 mg. Don't expect to feel anything for at least two weeks. Track with objective tools: spatial recall tests, word-pair memory tasks, mental rotation exercises. Subjective "feel" is unreliable with this compound.
Cycling recommended due to lack of long-term human safety data. Neurogenic effects are gradual and cumulative: do not expect acute cognitive changes. Some protocols suggest 2-4 weeks off between cycles. Discontinue if side effects emerge.
No long-term human safety data exists. LIF pathway competitive inhibition affects not only hippocampal neurogenesis but also neuroimmune balance (LIF is a pleotropic cytokine with systemic roles). Off-periods allow monitoring for cumulative immunological or neurological effects and avoid unknown risks from continuous LIF pathway modulation. Neurogenic effects appear structural and persistent in animal models: off-cycling does not appear to eliminate achieved neurogenesis.
Or use the universal Peptide Calculator for any peptide.
Expected: Mild improvement in memory consolidation and spatial recall by weeks 3–4, if SC route is effective for the individual. Many report no discernible effect from SC at beginner dose.
Monitor: Log baseline spatial/recall tasks. Reassess at week 4.
Gather supplies: lyophilized P21 vial, bacteriostatic water, alcohol swabs, insulin syringes (28 to 31 gauge for SC) or a nasal spray atomizer for intranasal. Refrigerate reconstituted solution at 2 to 8 degrees Celsius.
For SC: add 2 mL bacteriostatic water to a 10 mg vial (equals 5 mcg per microliter). For intranasal: add 1 mL to a 5 mg vial (equals 5 mg/mL, or 500 mcg per 0.1 mL spray).
For subcutaneous injection: swab the vial top and injection site with alcohol. Draw your dose (beginner 100 mcg equals 20 units; moderate 300 mcg equals 60 units; aggressive 500 mcg equals 100 units on a U100 syringe with the 10 mg/2 mL reconstitution). Inject into abdominal fat at a 45-degree angle. Rotate injection sites daily.
For intranasal administration: transfer reconstituted solution to a nasal spray atomizer. One spray of 0.1 mL delivers 500 mcg at the 5 mg/mL concentration. Administer one to two sprays per nostril as needed for your target dose.
No timing relative to meals is required.
If using the intranasal intermediate protocol, loading at 500 mcg for weeks 1 to 2 and stepping up to 1000 mcg for weeks 3 to 4 is the community top protocol.
Store reconstituted solution refrigerated at 2 to 8 degrees Celsius and use within 4 weeks. Lyophilized powder is stable at room temperature for up to 1 month but refrigeration is recommended regardless.
5–10× higher absolute dose than SC: 500 mcg–4 mg/day intranasally vs. 100–500 mcg/day SC
Most community users prefer intranasal. Requires nasal spray atomizer. Reconstitute to 5 mg/mL (5 mg vial + 1 mL BAC water) for practical intranasal volumes: each 0.1 mL spray delivers 500 mcg at this concentration. NOTE: calculator dosing tiers apply only to SC: do not use SC tiers for intranasal dosing.
100–500 mcg/day; matches dosing calculator tiers. At moderate dose (300 mcg SC): 5 mg vial lasts ~16 days, 10 mg vial ~33 days.
Standard abdominal or thigh SC injection. Rotate sites. Animal studies (PMID 20600002, 25485743) used SC administration. Beginner starting point due to lower cost per day vs. intranasal.
Complementary dual-mechanism stack: Semax provides rapid BDNF-like effects and acute cognitive enhancement; P21 provides slower, structural hippocampal neurogenesis. Different pathways: Semax via BDNF mimicry/5-HT system; P21 via LIF inhibition. Most commonly recommended stack for P21 in community.
P21 IN 500–1000 mcg + Semax IN 100–300 mcg, both morning
Anxiolytic complement. Selank modulates GABAergic and serotonergic pathways without sedation; P21 promotes neurogenesis. Non-overlapping mechanisms. Used to reduce cognitive anxiety/stress alongside P21's slow neurogenic action.
P21 IN 500–1000 mcg + Selank IN 100–300 mcg, both morning
Both promote hippocampal neurogenesis through different mechanisms: P21 via LIF/BDNF pathway, Dihexa via HGF/Met pathway. Community stacks these for aggressive neurogenesis. No safety data for combination; additive neurogenic stimulus is uncharacterized.
Use sequentially rather than simultaneously until interaction data exists
Broad neurotrophic factor mixture with established clinical use in stroke/neuroprotection. Combined with P21's targeted LIF/BDNF mechanism in neuroprotection research stacks. No formal interaction data.
Both P21 (LIF/BDNF pathway) and SSRIs (5-HT1A signaling) promote hippocampal neurogenesis through different mechanisms. Additive neurogenic stimulation is theoretically possible but unstudied. Serotonergic modulation may also interact with LIF pathway downstream signaling. Caution warranted; medical supervision recommended if co-administering.
P21's neurogenic stimulation may theoretically lower seizure threshold. Anti-epileptics alter neuronal excitability in ways that could interact unpredictably with LIF pathway modulation. No data exists.
LIF is a pleotropic cytokine involved in immune regulation. Competitive LIF inhibition by P21 could alter immunosuppressant drug effects in uncharacterized ways.
Pricing updated 2026-04-09
No human safety data exists for P21. That sentence needs to land before anything else. Every side effect profile below comes from animal studies and anecdotal community reports from a small user base (roughly 30 to 80 Reddit threads). Full-length CNTF, the parent protein P21 was derived from, caused weight loss, persistent cough, and antibody formation when tested in human ALS trials. P21 was specifically engineered to avoid those effects by using only four residues instead of the full protein. Whether the modification eliminates all CNTF-associated risks in humans is unknown because no human toxicology study has been performed. Community-reported side effects: headache is the most common, typically transient and concentrated in the first 3 to 5 days. Mild fatigue during initial dosing. Transient brain fog that usually resolves within a week. Intranasal irritation if using a nasal spray atomizer. None of these have been documented in controlled settings. The theoretical concerns deserve attention. P21 inhibits LIF signaling, and LIF is a pleiotropic cytokine with roles in immune regulation beyond just neurogenesis. Sustained LIF pathway modulation could theoretically affect neuroimmune balance. Mood destabilization, unusual fatigue, or inflammatory-type symptoms during a cycle may signal immune effects that warrant discontinuation. Neurogenic stimulation carries its own theoretical risk. Active cancer, especially CNS tumors, is a contraindication; promoting neural progenitor cell proliferation in someone with existing tumor biology could be dangerous. The under-25 population should avoid P21 because brain development is still ongoing. Pregnancy and breastfeeding: no reproductive toxicology data exists. Autoimmune neurological conditions are contraindicated because LIF pathway modulation may disrupt neuroimmune balance in unpredictable ways. Known hypersensitivity to CNTF-derived compounds is an obvious exclusion. Drug interactions: both P21 and SSRIs/SNRIs promote hippocampal neurogenesis through different pathways (LIF/BDNF versus 5-HT1A signaling). Combined effects are unstudied. Anti-epileptic medications may interact because neurogenic stimulation could theoretically lower seizure threshold. Immunosuppressants like methotrexate and cyclosporine could behave differently under LIF pathway inhibition. Stop immediately and consult a physician if you develop persistent headache beyond week 2, new focal neurological symptoms (visual, motor, or sensory changes), significant mood shifts, or signs of immune dysregulation.
Verify P21 dosing and safety with a second opinion
Research-only compound with no FDA-regulated manufacturing standard. Sold by gray-market research vendors with varying analytical rigor. No standardized injectable-grade formulation exists. Pre-made intranasal spray products have variable excipient quality and sterility assurance.
| Test | When | Target |
|---|---|---|
| Cognitive function self-assessment | Baseline before cycle; week 2; week 4; 2 weeks post-cycle | No specific target: looking for directional improvement from personal baseline |
| Mood and anxiety tracking | Weekly throughout cycle | — |
| Neurological symptom log | Daily during weeks 1–2, then weekly | — |
P21 has no acute subjective signal. Objective tasks (spatial recall, word-pair memory, mental rotation) are the only reliable way to detect benefit or worsening.
LIF pathway modulation affects neuroimmune balance. Immune dysregulation can present as mood shifts, unusual fatigue, or anxiety: early warning signs for discontinuation.
Absolute contraindication for CNS tumors and autoimmune neurological conditions. Any new headache pattern, visual changes, or focal neurological signs warrants immediate discontinuation.
No significant cognitive changes expected. Neurogenic processes are gradual. Any perceived effects during this window may be placebo. Animal studies show early increases in BDNF expression.
In mouse models, measurable increases in hippocampal neurogenesis and dendritic maturation occur within this window. Anecdotal reports describe subtle improvements in focus and memory recall.
Animal studies demonstrate peak neurogenic and cognitive effects by this period. Recommended cycle endpoint. Long-term mouse studies showed sustained benefits up to 18 months post-treatment, but human translatability is unknown.
Weeks 1 to 2 (Silent phase): Don't expect to feel anything. Animal data shows early BDNF upregulation and neural progenitor cell proliferation starting in the dentate gyrus subgranular zone, but no behavioral changes appeared in rodent studies at this stage. Community users confirm: any perceived improvement this early is likely placebo. Some people report mild headache or transient brain fog in the first 3 to 5 days, plus minor intranasal irritation if using spray. Weeks 2 to 4 (Neurogenesis acceleration): Animal models show measurable increases in hippocampal neurogenesis and dendritic maturation. Normal adult mice hit improved spatial reference memory at around week 4 (Bolognin et al.)[3]. Community users describe subtle improvements in memory consolidation and spatial recall. Some report vivid dreams, which gets interpreted as a neurogenesis signal. Verbal recall and language retrieval sometimes improve. Side effects are generally absent; occasional mild fatigue gets mentioned. Weeks 4 to 6 (Peak effect window): Peak tau reduction and neurogenesis occurred by this point in 3xTg-AD mice [1]. Synaptic plasticity improvements were sustained. This is the recommended cycle endpoint. Community users who complete a full cycle describe consistent but subtle gains, mostly in multi-step memory tasks, spatial navigation, and recall precision. No side effects typically reported at this stage. Post-cycle weeks 7 to 10 (Off-cycle monitoring): Animal studies tracked sustained neurogenic benefits persisting well beyond the dosing period, with one model showing effects at 18 months. Community users generally perceive cognitive improvements as retained during off-cycle. Some report gradual return to baseline by weeks 8 to 10 off-cycle. The 4-week off period is recommended given unknown long-term LIF pathway effects.
Early BDNF upregulation and neural progenitor cell proliferation in dentate gyrus subgranular zone (animal data). No measurable behavioral changes at this stage in rodent studies.
No perceivable effects. Any improvement at this stage is likely placebo. Some users report mild headache or transient brain fog in first 3–5 days.
Measurable increases in hippocampal neurogenesis and dendritic maturation in animal models. Improved spatial reference memory emerging at ~4 weeks in C57BL/6 normal adult mice (PMID 20600002).
Subtle improvements in memory consolidation and spatial recall. Some users report vivid dreams as a neurogenesis correlate. Verbal recall and language retrieval sometimes noted.
Peak tau reduction and neurogenesis in 3xTg-AD mice at 4–6 weeks (PMID 25485743). Sustained synaptic plasticity improvements. Human translatability timeline is unknown.
Most users complete cycle here. Improvements subtle but consistent: most notable in multi-step memory tasks, spatial navigation, and recall precision.
Animal studies show sustained neurogenic benefits persisting well beyond dosing period (18-month follow-up in some models). Reversal timeline in humans unknown.
Cognitive improvements generally perceived as retained during off-cycle. Some users report gradual return to baseline by week 8–10 off-cycle.
Source: Estimated plasma half-life >3 hours based on stability data (>90% stability in gastric juice, >97% in intestinal fluid at 37°C). No formal human PK studies published.
Loading the interactive decay curve.
P21 is classified as a research compound. It has no FDA approval, no investigational new drug (IND) authorization for clinical trials, and no Orphan Drug Designation. Phanes Biotech has been reported in IND-enabling stages, but no Phase I trial has been registered or initiated as of April 2026. P21 is not scheduled or controlled in the United States. It is sold by gray-market research chemical vendors under "for research purposes only" labeling. No compounding pharmacy formulation exists; there is no USP monograph or injectable-grade manufacturing standard. Athletes should note that while P21 is not explicitly listed on the World Anti-Doping Agency (WADA) prohibited list by name, the S2 category (peptide hormones and growth factors) and S0 category (unapproved substances) could apply. Check current WADA status before competing. This content is for educational and research reference only. P21 is not approved for human use. Consult a qualified healthcare provider before using any research compound.
Peptide Schedule Research TeamReviewed Apr 20265 Citations
